Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
International issues on the agenda as Frances's Macron visits China - 2Journalists killed by Israeli strike in southern Lebanon
- 3Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- 4Top Frozen yogurt Flavor: Cast Your Vote!
- 5Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- Arctic sea ice hits lowest winter level as heat records are shattered worldwide
- Vote In favor of Your Favored Language Interpretation Administration
- 'All Her Fault' ending explained: The shocking conclusion to the psychological thriller inspired by true events
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
- Fireball sightings are surging across the US — here's what's really going on
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- Sexual violence part of 'everyday life' in parts of Sudan, charity says
- Figure out How to Back Your Rooftop Substitution
